Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Mimedx Group (MDXG) EBIT Margin: 2011-2025

Historic EBIT Margin for Mimedx Group (MDXG) over the last 15 years, with Sep 2025 value amounting to 19.51%.

  • Mimedx Group's EBIT Margin rose 623.00% to 19.51% in Q3 2025 from the same period last year, while for Sep 2025 it was 13.69%, marking a year-over-year decrease of 477.00%. This contributed to the annual value of 16.87% for FY2024, which is 533.00% up from last year.
  • Latest data reveals that Mimedx Group reported EBIT Margin of 19.51% as of Q3 2025, which was up 55.54% from 12.55% recorded in Q2 2025.
  • In the past 5 years, Mimedx Group's EBIT Margin registered a high of 26.89% during Q2 2024, and its lowest value of -15.79% during Q1 2022.
  • In the last 3 years, Mimedx Group's EBIT Margin had a median value of 13.34% in 2023 and averaged 13.94%.
  • In the last 5 years, Mimedx Group's EBIT Margin surged by 2,775bps in 2023 and then plummeted by 1,435bps in 2025.
  • Mimedx Group's EBIT Margin (Quarterly) stood at 2.53% in 2021, then skyrocketed by 1,268bps to 15.21% in 2022, then spiked by 263bps to 17.84% in 2023, then slumped by 594bps to 11.90% in 2024, then surged by 623bps to 19.51% in 2025.
  • Its EBIT Margin was 19.51% in Q3 2025, compared to 12.55% in Q2 2025 and 9.35% in Q1 2025.